Galapagos (Nasdaq:GLPG) - Cotización, noticias y análisis

Resumen de acción GLPG

Galapagos NV, empresa biotecnológica, desarrolla medicamentos centrados en la oncología y la inmunología principalmente en Estados Unidos y Europa.

Acerca de la empresa

GLPG fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	2/6
Financial Health	6/6
Dividends	0/6

Recompensas

Ha pasado a ser rentable este año

Análisis de riesgos

Se prevé que los beneficios disminuyan un promedio de 30.2% al año durante los próximos 3 años

Grandes partidas extraordinarias que afectan a los resultados financieros

Competidores de Galapagos NV

Dynavax Technologies

NasdaqGS:DVAX

US$1.5b

MiMedx Group

NasdaqCM:MDXG

US$1.2b

Catalyst Pharmaceuticals

NasdaqCM:CPRX

US$2.0b

Alkermes

NasdaqGS:ALKS

US$4.1b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Galapagos
Historical stock prices
Current Share Price	€28.38
52 Week High	€45.21
52 Week Low	€28.30
Beta	0.038
1 Month Change	-2.41%
3 Month Change	-26.61%
1 Year Change	-36.17%
3 Year Change	-61.20%
5 Year Change	-75.73%
Change since IPO	261.53%

Noticias y actualizaciones recientes

Galapagos: Pipeline Still Progressing Despite Financial Volatility

Mar 07

Recent updates

Galapagos: Pipeline Still Progressing Despite Financial Volatility

Mar 07

Galapagos: Trading At Discount To Cash With A Fast-Growing Marketed Product

Oct 10

EMA panel approves amending label for Galapagos' Jyseleca on testicular function effects

Oct 03

Galapagos, Gilead's Selection study on filgotinib in ulcerative colitis published in the Lancet

Jun 04

Galapagos reports Q1 results

May 06

Galapagos: Market Values Pipeline Below $0

Dec 30

Galapagos candidate shows positive action in IPF proof-of-concept study

Nov 30

Galapagos NV 2020 Q3 - Results - Earnings Call Presentation

Nov 06

Galapagos Is A Buy Despite Setback In The U.S.

Oct 23

Rentabilidad de los accionistas

	GLPG	US Biotechs	Mercado US
7D	-0.9%	0.7%	1.2%
1Y	-36.2%	5.0%	27.7%

Rentabilidad vs. Industria: GLPG obtuvo unos resultados inferiores a los del sector US Biotechs , que el año pasado arrojó un rendimiento del -2.3%.

Rentabilidad vs. Mercado: GLPG obtuvo unos resultados inferiores a los del mercado US, que fue del 24.9% el año pasado.

Volatilidad de los precios

Is GLPG's price volatile compared to industry and market?
GLPG volatility
GLPG Average Weekly Movement	3.5%
Biotechs Industry Average Movement	11.2%
Market Average Movement	5.9%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	2.8%

Precio estable de las acciones: El precio de las acciones de GLPG ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de GLPG (4%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1999	1,123	Paul Stoffels	www.glpg.com

Galapagos NV, empresa biotecnológica, desarrolla medicamentos centrados en la oncología y la inmunología principalmente en Estados Unidos y Europa. Los productos en fase de desarrollo de la empresa son GLPG3667, que ha finalizado el ensayo de fase 1b; GLPG5101, un candidato a producto CD19 CAR-T fabricado en el punto de atención, actualmente en ensayo de fase 1/2 en linfoma no hodgkiniano recidivante/refractario; GLPG5201, un producto candidato CD19 CAR-T fabricado en el punto de atención, actualmente en ensayo de fase 1/2 en leucemia linfocítica crónica recidivante/refractaria; y GLPG5301, un producto candidato BCMA CAR-T fabricado en el punto de atención, actualmente en ensayo de fase 1/2 en mieloma múltiple recidivante/refractario. La empresa tiene acuerdos de colaboración con Gilead Sciences, Inc. y AbbVie S.à r.l.

Resumen de fundamentos de Galapagos NV

¿Cómo se comparan los beneficios e ingresos de Galapagos con su capitalización de mercado?
Estadísticas fundamentales de GLPG
Capitalización bursátil	US$1.89b
Beneficios(TTM)	US$33.34m
Ingresos (TTM)	US$264.42m

56.7x

Ratio precio-beneficio (PE)

7.1x

Ratio precio-ventas (PS)

¿Está GLPG sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de GLPG
Ingresos	€243.58m
Coste de los ingresos	€262.90m
Beneficio bruto	-€19.31m
Otros gastos	-€50.02m
Beneficios	€30.71m

Últimos beneficios comunicados

Mar 31, 2024

Próxima fecha de beneficios

Aug 01, 2024

Beneficios por acción (BPA)	0.47
Margen bruto	-7.93%
Margen de beneficio neto	12.61%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado GLPG a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción GLPG

Recompensas

Análisis de riesgos

Competidores de Galapagos NV

NasdaqGS:DVAX

US$1.5b

NasdaqCM:MDXG

US$1.2b

NasdaqCM:CPRX

US$2.0b

NasdaqGS:ALKS

US$4.1b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Galapagos NV Announces Board Changes

Galapagos: Pipeline Still Progressing Despite Financial Volatility

Galapagos NV to Present New Preliminary Translational Data at EBMT-EHA Annual Meeting 2024

Alfasigma S.p.A. completed the acquisition of Filgotinib business from Galapagos NV (ENXTAM:GLPG).

Michele Manto to Join Alfasigma and Resigns from His Position as Chief Commercial Officer and Executive Committee Member At Galapagos

Galapagos Announces Start of PAPILIO-1 Phase 1/2 Multiple Myeloma Study of Point-Of-Care Manufactured BCMA CAR-T Candidate, GLPG5301

Recent updates

Galapagos NV Announces Board Changes

Galapagos: Pipeline Still Progressing Despite Financial Volatility

Galapagos NV to Present New Preliminary Translational Data at EBMT-EHA Annual Meeting 2024

Alfasigma S.p.A. completed the acquisition of Filgotinib business from Galapagos NV (ENXTAM:GLPG).

Michele Manto to Join Alfasigma and Resigns from His Position as Chief Commercial Officer and Executive Committee Member At Galapagos

Galapagos Announces Start of PAPILIO-1 Phase 1/2 Multiple Myeloma Study of Point-Of-Care Manufactured BCMA CAR-T Candidate, GLPG5301

Galapagos Presents New Encouraging Clinical Data from the Ongoing Phase 1/2 CD19 CAR-T Studies with GLPG5201 and GLPG5101

Galapagos NV to Report First Half, 2024 Results on Aug 01, 2024

Galapagos NV Announces Board Changes

Galapagos NV to Report Q4, 2023 Results on Mar 28, 2024

Galapagos NV Announces Start of Phase 2 Study with Selective Tyk2 Inhibitor, GLPG3667, in Patients with Active Systemic Lupus Erythematosus

Galapagos NV Revises Sales Guidance for the Full Year 2023

Galapagos Appoints Thad Huston as Chief Financial Officer, Effective from July 1, 2023

Galapagos NV Announces Director Changes

Galapagos to Showcase CAR-T Point-Of-Care Manufacturing and Initial Phase 1/2 CLL Data with CD19 CAR-T Candidate, GLPG5201, at the EHA 2023 Congress

Galapagos NV Announces Topline Results from Phase 3 DIVERSITY Trial of Filgotinib in Crohn’s Disease

Galapagos NV Announces Changes in the Executive Committee Effective 1 January 2023

Galapagos and CellPoint Presented Encouraging Initial Data AtASH 2022 for GLPG5101, a CD19 CAR-T Candidate Manufactured At Point-Of-Care

Galapagos Announces CHMP Adoption of PRAC’s Recommendation for Jyseleca® Following Extensive Safety Review of all JAK Inhibitors

Galapagos NV to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022

Galapagos NV to Report Fiscal Year 2022 Final Results on Mar 23, 2023

Galapagos NV to Report Q1, 2023 Results on May 04, 2023

Galapagos: Trading At Discount To Cash With A Fast-Growing Marketed Product

Galapagos Receives Positive CHMP Opinion for Jyseleca® European Label Update Based on Testicular Function Safety Data from MANTA/RAy Studies

EMA panel approves amending label for Galapagos' Jyseleca on testicular function effects

Galapagos NV announced that it has received €3.07625 million in funding

Galapagos NV Revises Revenue Guidance of Jyseleca for the Full Year 2022

Galapagos stock dips after Jefferies slashes rating citing challenges ahead

Galapagos NV (ENXTAM:GLPG) entered into a definitive agreement to acquire Abound Bio, Inc. for $14 million.

Galapagos NV announced that it expects to receive €1.459507 million in funding

Galapagos: Can The Company Turn Around?

Galapagos NV to Report Q3, 2022 Results on Nov 03, 2022

Galapagos NV Announces Executive Appointments

Galapagos NV Announces Approval of Additional Indication Based on Phase 2B/3 SELECTION Study in Patients with Moderate-To-Severe Ulcerative Colitis

Galapagos: A History Of Disruptive Failures

Galapagos Provides Further Insights into the Treatment of Ulcerative Colitis At the European Crohn’s and Colitis Organization Annual Congress

Galapagos NV Announces Authorization of Medicines and Healthcare Products Regulatory Agency for Jyseleca (Filgotinib), as New Treatment for Ulcerative Colitis in Great Britain

Galapagos: The Investment Thesis Is More Appealing Than Ever

Galapagos Nv Completes Patient Recruitment for Mangrove Phase 2 Trial with GLPG2737 in Polycystic Kidney Disease

Galapagos Announces Positive CHMP Opinion for Jyseleca® (Filgotinib) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

Galapagos NV Demonstrates Early Clinical Activity with SIK2/3 Inhibition in Inflammation

Galapagos NV Announces That Primary and Secondary Endpoint Results from the Phase 3 SELECTIONinduction

Galapagos, Gilead's Selection study on filgotinib in ulcerative colitis published in the Lancet

Galapagos NV to Present Data on Rheumatoid Arthritis At the Upcoming European League Against Rheumatism (EULAR) Congress

Galapagos Announces First Patient Enrolled in FILOSOPHY Study to Advance Understanding of Jyseleca (Filgotinib) Effectiveness and Safety in A Real-World Setting

Galapagos reports Q1 results

Galapagos Reports Primary Endpoint for the Ongoing Filgotinib MANTA and MANTA-RAy Safety Studies

Galapagos NV to Report Fiscal Year 2020 Final Results on Mar 25, 2021

Galapagos and Gilead discontinue ISABELA Phase 3 trials in IPF

Galapagos NV to Report Fiscal Year 2021 Results on Feb 24, 2022

NICE Recommends Galapagos Jyseleca (Filgotinib) on NHS in Decision for Rheumatoid Arthritis

Selvita S.A. (WSE:SLV) completed the acquisition of Fidelta D.O.O. from Galapagos NV (ENXTAM:GLPG).

Galapagos: Market Values Pipeline Below $0

Gilead Sciences, Inc. and Galapagos NV Announce New Commercialization and Development Agreement for Jyseleca® (Filgotinib)

Galapagos NV Reports Positive Topline Results with GLPG1205 in IPF Patients in PINTA Proof-of-Concept Trial

Galapagos NV Announces First Dosing in MANGROVE Phase 2 Trial with GLPG2737 in Polycystic Kidney Disease

Galapagos candidate shows positive action in IPF proof-of-concept study

Selvita S.A. (WSE:SLV) signed an agreement to acquire 100% stake in Fidelta D.O.O. from Galapagos NV (ENXTAM:GLPG) for an enterprise value of €31.2 million.

Galapagos NV Announces Dosing of the First Psoriasis Patient in the Phase 1B Trial with GLPG3667